Main content

    Amyotrophic Lateral Sclerosis (ALS)/Alzheimer's Disease

    The Forbes Norris MDA/ALS Research Center


    Amyotrophic Lateral Sclerosis (ALS)  |  Cognitive Decline

    Amyotrophic Lateral Sclerosis (ALS)

    Principal Investigator/Contact Information Protocol Title Patient Population Recruitment Period
    Principal Investigator:
    Jonathan Katz, MD

    Contact:
    Marguerite Engel
    415-600-3758
    Email engelm@cpmcri.org    		 Clinical Trial of Ceftriaxone in Subjects with ALS
    		Patients with amyotrophic lateral sclerosis (ALS) also known as Lou Gehrig's disease. Active/Enrolling
    Principal Investigator:
    Jonathan Katz, MD

    Contact:
    Will Harris
    415-600-3967
    Email harriscw@cpmcri.org    		 Multicenter ALS Cohort Study of Oxidative Stress and Disease ProgressionPatients with amyotrophic lateral sclerosis (ALS) also known as Lou Gehrig's disease. Active/Enrolling
    Principal Investigator:
    Jonathan Katz, MD

    Contact:
    Marguerite Engel
    415-600-3758
    Email EngelM@cpmcri.org    		 A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of the Safety and Efficacy of Dexpramipexole in Subjects With Amyotrophic Lateral Sclerosis Patients with amyotrophic lateral sclerosis (ALS) also known as Lou Gehrig's disease. Active/Enrolling
    Principal Investigator:
    Jonathan Katz, MD

    Contact:
    Giovanna Kushner
    415-600-3983
    Email KushneG@cpmcri.org    		 Average Volume Assured Pressure Support (AVAPS) in ALS Patients with Nocturnal Hypoventilation: A Randomized Crossover Trial Patients with amyotrophic lateral sclerosis (ALS) also known as Lou Gehrig's disease. Active/Enrolling
    Principal Investigator:
    Jonathan Katz, MD

    Contact:
    Will Harris
    415-600-3967
    Email HarrisCW@cpmcri.org    		 Clinically Meaningful Changes (CMC) Scale in the MDA/ALS Clinical Network Patients with amyotrophic lateral sclerosis (ALS) also known as Lou Gehrig's disease. Active/Enrolling
    Principal Investigator:
    Jonathan Katz, MD

    Contact:
    Will Harris
    415-600-3967
    Email HarrisCW@cpmcri.org    		 A Phase II, Double-Blind, Randomized, Three-Way Crossover, Placebo-Controlled, Pharmacodynamic Study of CK-2017357 in Patients with Generalized Myasthenia Gravis Patients with amyotrophic lateral sclerosis (ALS) also known as Lou Gehrig's disease. Active/Enrolling


    Back to top

    Cognitive Decline

    Principal Investigator/Contact Information Protocol Title Patient Population Recruitment Period
    Principal Investigator:
    Catherine Madison, MD

    Contact:
    Thais Zayas-Bazan
    415-600-5764
    Email zayast@cpmcri.org    		Predicition of Cognitive Decline with MRI and MRSISubjects 60 years of age or older who have mild problems with their memory and are comfortable undergoing MRI; healthy volunteers are also neededOpen


    updated: 3/2011

    Back to top